Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma.
OBJECTIVE
To evaluate the efficacy of different variants of immunotherapy, namely, adoptive LAK-therapy, vaccine therapy and their combination in vivo using transplantable murine MC-rhabdomyosarcoma resistant and sensitive to doxorubicin (Dox).


METHODS
The study was carried out on BALB/c mice bearing Dox-sensitive and Dox-resistant transplantable murine MC-rhabdomyosarcoma. LAK-therapy (using lymphocytes from lymph nodes of syngenic mice) was performed starting from day 7 after tumor cell transplantation for 5 days; LAK (3 x 10(6) cells in 0.2 ml medium) were injected in the region of tumor. The vaccine prepared on the base of tumor cell glycopeptides was administered intraperitoneally at the volume of 0.2 ml before or after tumor transplantation. Efficacy of immunotherapy was evaluated by tumor growth inhibition and life span of animals.


RESULTS
By the indexes of tumor growth inhibition and average life span, for animals bearing Dox-sensitive tumors vaccine therapy was the most effective, whilst adoptive LAK-therapy was the most effective for mice bearing Dox-resistant tumors. All applied variants of therapy - adoptive LAK-therapy, vaccine therapy and their combination were effective for treatment of mice bearing Dox-sensitive and Dox-resistant transplantable murine MC-rhabdomyosarcoma.


CONCLUSIONS
The obtained data demonstrated that Dox-sensitive and Dox-resistant tumors differ by the sensitivity to different types of immunotherapy.
Belova
O B
OB
RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine.
Vinnichuk
U D
UD
Shlakhovenko
V A
VA
Berezhnaya
N M
NM
D019264:Adoptive Transfer; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D007167:Immunotherapy / Q000379:methods; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D012208:Rhabdomyosarcoma / Q000628:therapy*
D000903:Antibiotics, Antineoplastic; D019496:Cancer Vaccines; D004317:Doxorubicin